16- https://doi.org/10.1182/blood-2021-146503
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
Translate Article 
Take Notes Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
- Abstract
- 4
- 10.1182/blood-2021-146585
- Nov 5, 2021
- Blood
A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia
- Abstract
- 3
- 10.1182/blood-2019-122778
- Nov 13, 2019
- Blood
Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study
- Abstract
- 26
- 10.1182/blood-2019-129107
- Nov 13, 2019
- Blood
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial
- Abstract
- 11
- 10.1182/blood-2019-128302
- Nov 13, 2019
- Blood
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
- Abstract
- 20
- 10.1182/blood-2019-124492
- Nov 13, 2019
- Blood
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel
- Abstract
- 3
- 10.1182/blood-2019-128909
- Nov 13, 2019
- Blood
Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
- Abstract
- 6
- 10.1182/blood-2019-125039
- Nov 13, 2019
- Blood
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort
- Abstract
- 3
- 10.1182/blood-2020-136408
- Nov 5, 2020
- Blood
Worldwide Examination of Patients with CLL Hospitalized for COVID-19
- Abstract
- 17
- 10.1182/blood-2019-127803
- Nov 13, 2019
- Blood
Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial
- Abstract
- 10.1182/blood-2020-140153
- Nov 5, 2020
- Blood
Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia
- Abstract
- 20
- 10.1182/blood-2020-138983
- Nov 5, 2020
- Blood
Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara Trial
- Abstract
- 5
- 10.1182/blood-2019-123747
- Nov 13, 2019
- Blood
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
- Abstract
- 15
- 10.1182/blood-2019-122073
- Nov 13, 2019
- Blood
Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
- Abstract
- 50
- 10.1182/blood-2019-129097
- Nov 13, 2019
- Blood
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
- Abstract
- 11
- 10.1182/blood-2021-155068
- Dec 4, 2021
- Blood
Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
What is the difference between bacteria and viruses?
What is the function of the immune system?Can diabetes be passed down from one generation to the next?